Diphyllobothriasis medical therapy: Difference between revisions
Jump to navigation
Jump to search
Usama Talib (talk | contribs) |
m (Bot: Removing from Primary care) |
||
| (4 intermediate revisions by 3 users not shown) | |||
| Line 12: | Line 12: | ||
===Antimicrobial Regimen=== | ===Antimicrobial Regimen=== | ||
The | The dose for empiric treatment of [[diphyllobothriasis]] is as follows:<ref name="urlCDC - DPDx - Diphyllobothriasis">{{cite web |url=https://www.cdc.gov/dpdx/diphyllobothriasis/index.html |title=CDC - DPDx - Diphyllobothriasis |format= |work= |accessdate=}}</ref><ref name="pmid19136438">{{cite journal |vauthors=Scholz T, Garcia HH, Kuchta R, Wicht B |title=Update on the human broad tapeworm (genus diphyllobothrium), including clinical relevance |journal=Clin. Microbiol. Rev. |volume=22 |issue=1 |pages=146–60, Table of Contents |year=2009 |pmid=19136438 |pmc=2620636 |doi=10.1128/CMR.00033-08 |url=}}</ref> | ||
* '''Diphyllobothriasis''' | * '''Diphyllobothriasis''' | ||
** 1.1 '''Adult''' | ** 1.1 '''Adult''' | ||
***Preferred regimen (1): [[Praziquantel]] 5-10 mg/kg orally in a single-dose therapy | ***Preferred regimen (1): [[Praziquantel]] 5-10 mg/kg orally in a single-dose therapy. | ||
*** Alternative regimen (1): [[Niclosamide]] 2 gm single dose orally for adults | *** Alternative regimen (1): [[Niclosamide]] 2 gm single dose orally for adults. | ||
** 1.2 '''Children''' | |||
***Preferred regimen (1): [[Praziquantel]] 5-10 mg/kg orally in a single-dose therapy. | |||
*** Alternative regimen (1): [[Niclosamide]] 50 mg/kg (max 2 gm) orally once. | |||
===Mechanism of action=== | ===Mechanism of action=== | ||
| Line 27: | Line 30: | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
{{WH}} | |||
{{WS}} | |||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category: Foodborne illnesses]] | [[Category:Foodborne illnesses]] | ||
[[Category:Needs overview]] | |||
[[Category:Emergency medicine]] | |||
[[Category:Up-To-Date]] | |||
[[Category:Infectious disease]] | [[Category:Infectious disease]] | ||
[[Category: | [[Category:Gastroenterology]] | ||
Latest revision as of 21:24, 29 July 2020
|
Diphyllobothriasis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Diphyllobothriasis medical therapy On the Web |
|
American Roentgen Ray Society Images of Diphyllobothriasis medical therapy |
|
Risk calculators and risk factors for Diphyllobothriasis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Kalsang Dolma, M.B.B.S.[2], Furqan M M. M.B.B.S[3]
Overview
Medical therapy is the primary modality of treatment for diphyllobothriasis. Drugs used for diphyllobothriasis include either praziquantel or niclosamide.
Medical Therapy
The medications used in the treatment of diphyllobothriasis are:[1][2]
Antimicrobial Regimen
The dose for empiric treatment of diphyllobothriasis is as follows:[1][2]
- Diphyllobothriasis
- 1.1 Adult
- Preferred regimen (1): Praziquantel 5-10 mg/kg orally in a single-dose therapy.
- Alternative regimen (1): Niclosamide 2 gm single dose orally for adults.
- 1.2 Children
- Preferred regimen (1): Praziquantel 5-10 mg/kg orally in a single-dose therapy.
- Alternative regimen (1): Niclosamide 50 mg/kg (max 2 gm) orally once.
- 1.1 Adult
Mechanism of action
- Praziquantel
- Oral praziquantel is available for human use in the United States. Praziquantel increases the permeability of the cell membrane towards calcium ions. This induces contraction of the parasites, resulting in paralysis in the contracted state.
- Niclosamide
- Niclosamide inhibits the oxidative phosphorylation and anaerobic metabolism in the parasites.
References
- ↑ 1.0 1.1 "CDC - DPDx - Diphyllobothriasis".
- ↑ 2.0 2.1 Scholz T, Garcia HH, Kuchta R, Wicht B (2009). "Update on the human broad tapeworm (genus diphyllobothrium), including clinical relevance". Clin. Microbiol. Rev. 22 (1): 146–60, Table of Contents. doi:10.1128/CMR.00033-08. PMC 2620636. PMID 19136438.